Benzinga

OCTOBER 2, 2023

BOSTON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Klogenix LLC ("Klogenix" or "the Company") is pleased to announce that its intellectual property portfolio has been acquired by ADvantage Therapeutics, Inc. has been appointed Chief Science Officer at the acquiring company. ADvantage Therapeutics Inc. Abraham, Ph.D.

45

45

Harvard Corporate Governance

JULY 8, 2022

Posted by Subodh Mishra, Institutional Shareholder Services, Inc., Posted by Scott Hirst (Boston University), and Adriana Robertson (University of Chicago), on Wednesday, July 6, 2022. VICI Properties: Creating Value from the Ashes of Caesar’s Demise. Shareholder Resolutions in Review: Lobbying Disclosures.

Capital Structure 201

Capital Structure Finance 201

Benzinga

MAY 2, 2023

Boston, May 02, 2023 (GLOBE NEWSWIRE) -- Gordon Brothers, the global advisory and investment firm, in a joint venture with Nations Capital Inc., Boston, May 02, 2023 (GLOBE NEWSWIRE) -- Gordon Brothers, the global advisory and investment firm, in a joint venture with Nations Capital Inc.,

40

40

Benzinga

OCTOBER 6, 2023

Special dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. About Tourmaline Bio, Inc. About Talaris Therapeutics, Inc. Talaris Therapeutics, Inc.,

Dividends 40

Dividends Banking Marketability 40

Benzinga

MARCH 5, 2024

BOSTON and PLEASANTON, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ: AKTX ), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, and Peak Bio Inc. In addition, the program includes a novel pre-clinical ADC candidate targeting TROP-2.

Alpha 40

Alpha Equity Technology Marketability 40

Benzinga

MARCH 5, 2024

BOSTON and PLEASANTON, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ: AKTX ), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, and Peak Bio Inc. In addition, the program includes a novel pre-clinical ADC candidate targeting TROP-2.

Alpha 40

Alpha Equity Technology Marketability 40

Benzinga

JUNE 22, 2023

8 million and approximately 21.3 % of the combined company BOSTON and NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. 8 million and approximately 21.3 % of the combined company BOSTON and NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. in May 2022.

Dividends 40

Dividends Finance 40